louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00288743: Adherence, Efficacy and Safety of an Insulin Protocol in the Critically Ill: A Prospective Observational Study
Official title: Adherence, Efficacy and Safety of an Insulin Protocol in the Critically Ill: A Prospective Observational Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Critically Ill Patients
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2006-02-08
Enrollment: 30
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: There is a growing body of evidence in the literature regarding the adverse effects of hyperglycemia in critically ill patients. To target and maintain better blood glucose regulation we implemented an insulin protocol with target blood glucose levels between 81-110 mg/dL.


Eligibility criteria: Inclusion Criteria:

* Surgical or medical critically ill patients
* An expected ICU-stay of more than 72 hours
* Age \> 16 years
* Need for insulin therapy
* Patients must have an arterial line

Exclusion Criteria:

* Patients who did not respond to the inclusion criteria
* Patients with diabetic ketoacidosis
* Cardiac surgical patients
* Patients transferred from other hospitals
* Other study enrollment

Primary outcomes:
measure: To evaluate compliance, efficacy and safety of an insulin protocol, with target glycemia between 81-110 mg/dL in critically ill patients
Secondary outcomes:
measure: To determine potential factors associated with blood glucose control
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Hospital Ghent
Study officials:
affiliation: University Hospital, Ghent
name: Sandra Oeyen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01193543: Effect of Calanus Oli on Intra-abdominal Fat, Glucose Tolerance and Lipids in Man
Official title: Effect of Calanus Oli on Intra-abdominal Fat, Glucose Tolerance and Lipids in Man
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Overweight
Lead sponsor: University of Tromso
Sponsor class: OTHER
First posted: 2010-09-02
Enrollment: 117
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Preliminary studies in rats and mice indicate that calanus oil reduce accumulation of intra-abdominal fat. Pilot studies in humans have shown no adverse effects. In the present study 120 subjects, males and females, 20-65 years old, BMI 25-30 kg/m2 will be included and given calanus oli 1 g twice daily versus placebo for 1 year. The hypothesis is that calanus oil will reduce intra-abdominal fat, improve glucose tolerance and lipid profile.


Eligibility criteria: Inclusion Criteria:

* Body Mass Index (BMI) 25-30 kg/m2
* age 20-65 years

Exclusion Criteria:

* diabetes
* coronary heart disease last 12 months
* unstable angina pectoris
* cancer diagnosed the last 5 years
* use of lipid lowering drugs
* seafood allergy

Primary outcomes:
measure: Intra-abdominal fat as measured with CT scan
timeFrame: at the end of 12 months intervention
Secondary outcomes:
measure: oral glucose tolerance test
timeFrame: at the end of 12 months intervention
measure: lipid status
timeFrame: at the end of 12 months intervention
measure: systolic and diastolic blood pressure
timeFrame: at the end of 12 months intervention
measure: markers of inflammation - C-reactive protein (CRP)
timeFrame: at the end of 12 months intervention
measure: body weight
timeFrame: at the end of 12 months intervention
Other outcomes:
Locations:
city: Tromso
country: Norway
facility: University of Tromso
Study officials:
affiliation: University of Tromso
name: Rolf Jorde, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05110443: A Comparison of Static and Dynamic PET/CT (HYPOTHESIS Generation Study)
Official title: A Comparison of Static and Dynamic PET/CT in Patients With Malignancies, Infections and Inflammatory Diseases (HYPOTHESIS Generation Study)
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Oncology
Infections
Inflammation
Keywords: PET/CT
FDG
Dynamic Whole-Body
Lead sponsor: Aarhus University Hospital
Sponsor class: OTHER
First posted: 2021-11-08
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The general purpose of this initial study is to evaluate whether parametric PET/CT improves diagnosis and treatment monitoring in select diseases. The specific aim of the HYPOTHESIS GENERATION study is:

1. To obtain and compare parametric as well as traditional static PET/CT images and determine the number of lesions identified on each type of scan.

Detailed description: The hypothesis generating study will include a wide range of patients scheduled for PET/CT as part of either pre-therapy staging or treatment response.

Most scans will be performed with FDG, with indications for PET/CT including hematological, urogenital, thoracic and gynecological malignancies as well as patients with suspected infections and inflammation. We will also include patients referred for PET/CT using other radiotracers, such as tumour markers (68Ga-DOTATOC, 18F-FDOPA, 68Ga-PSMA, 18F-PSMA).

Instead of the usual procedure of having the injection of the radiotracer in the waiting room and having to wait 60 minutes before being moved to the scanner room for imaging, the study participants will be injected with the radiotracer already laying on the scanner bed and the scan will commence immediately.

Therefore, in this study the patients are still only being scanned once, but we are gathering PET information in a different way.

Eligibility criteria: Inclusion Criteria:

* Patients with a planned clinical standard PET/CT as part of pre-therapeutic staging, response assessment scanning or evaluation of infection/inflammation.
* Good performance status, which permits patients to lay still in the scanner for ca. 70 min.

Exclusion Criteria:

* Age \< 18 or \> 85 years
* Patients that can not tolerate a PET scan (f.ex: claustrophobia).

Primary outcomes:
measure: Obtaining a database of parametric and traditional static PET/CT images for comparison of visual and semiquantitative evaluation
timeFrame: through study completion, average 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Aarhus University Hospital
Study officials:
References:
Clinical trial NCT03939143: A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fasting State
Official title: Randomized, Open Label, Single Oral Administration at Fasting State, 2 x 2 Crossover Study to Investigate the Bioequivalence Test of DA-1229_01(A)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Type2 Diabetes
Lead sponsor: Dong-A ST Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2019-05-06
Enrollment: 34
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: A study demonstrates the bioequivalence of DA-1229_01(A) at Fasting State when compared with Sugamet sustained-release(SR) Tab 5/1000mg® in healthy adults


Eligibility criteria: Inclusion Criteria:

* Adult patients over 19 years of age at the time of health examination
* Female patients who were confirmed to be not pregnant at health examination
* Patients without a history of mental illness in the past 5 years

Exclusion Criteria:

* Patients who have taken medications which could affect the results of the clinical trial in the past 10 days of participating in the clinical trial
* Patients with a congestive heart failure which requires medicinal treatment
* Patients who have made a whole blood donation in the past 2 months or an apheresis donation in the past 2 weeks of participating in the clinical trial
* Female patients who are lactating

Primary outcomes:
measure: Area under the concentration-time curve(AUCt)
timeFrame: Hour -1 ~ Hour 72
measure: Maximum plasmaconcentration of drug in plasma(Cmax)
timeFrame: Hour -1 ~ Hour 72
Secondary outcomes:
measure: Area under the plasma drug concentration-time curve from time 0 to infinity(AUCinf)
timeFrame: Hour -1 ~ Hour 72
measure: AUCt/AUCinf
timeFrame: Hour -1 ~ Hour 72
measure: Time to reach the maximum plasma concentration(Tmax)
timeFrame: Hour -1 ~ Hour 72
measure: Terminal elimination rate constant(ramda z)
timeFrame: Hour -1 ~ Hour 72
measure: Terminal elimination half-life(t1/2)
timeFrame: Hour -1 ~ Hour 72
Other outcomes:
Locations:
city: Anyang-si
country: Korea, Republic of
facility: Metro Hospital
state: Gyeonggi-do
Study officials:
affiliation: Metro Hospital
name: Sung Dae Kwon, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00230490: Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201
Official title: Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Hepatitis B, Chronic
Keywords: Hepatitis B, Chronic
Hepatitis B Virus
Pradefovir Mesylate
Adefovir Dipivoxyl
Lead sponsor: Bausch Health Americas, Inc.
Sponsor class: INDUSTRY
First posted: 2005-09-30
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Compare the long-term safety of pradefovir to adefovir dipivoxyl

Detailed description: * Compare the long-term safety of pradefovir to adefovir dipivoxyl
* Monitor development of resistance
* Evaluate virologic and biochemical response

Eligibility criteria: Inclusion Criteria:

* Patients who completed 48 weeks of treatment in study RNA200103-201

Exclusion Criteria:

* Patients who were determined to be treatment failures in study RNA200103-201
* Patients who experienced a serious adverse event judged to be related to study drug in study RNA200103-201
* Patients with a serum creatinine greater than 2.0 mg/dl on two consecutive determinations in study RNA200103-201

Primary outcomes:
measure: - Safety: Clinical examinations of laboratory tests
measure: - Efficacy: Change in viral load over time
Secondary outcomes:
measure: - Efficacy: Proportion of patients with undetectable viral load
Other outcomes:
Locations:
Study officials:
affiliation: Bausch Health Americas, Inc.
name: Ralph T. Doyle
role: STUDY_DIRECTOR
References:
Clinical trial NCT04573790: A Modified Rabbit Training Model for Establishing an Emergency Front of Neck Airway in Children
Official title: A Modified Rabbit Training Model for Establishing an Emergency Front of Neck Airway in Children
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Emergency Front of Neck Airway in Children
Keywords: Cannot intubate, cannot oxygenate in children
emergency front of neck airway
rabbit cadaver model
emergency tracheotomy
Lead sponsor: University Children's Hospital, Zurich
Sponsor class: OTHER
First posted: 2020-10-05
Enrollment: 29
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Anesthesiologists working at the department of Anesthesia at University Children's Hospital Zurich

Brief summary: A "cannot intubate, cannot oxygenate" (CICO) situation is rare in paediatric anaesthesia, but can always occur in children under certain emergency situations. There is a paucity of literature on specific procedures for securing an emergency invasive airway in children under the age of 6 years. A modified emergency Front Of Neck Access (eFONA) technique using a rabbit cadaver model was developed to teach invasive airway protection in a CICO situation in children.

After watching an instructional video of our eFONA technique (tracheotomy, initial intubation with Frova catheter over which an endotracheal tube is inserted), 29 anaesthesiologists will perform two separate attempts on rabbit cadavers. The primary outcome is the success rate and the performance time overall and in subgroups of trained and untrained participants.


Eligibility criteria: Inclusion Criteria:

* Anesthesiologists working at the department of Anesthesia at University Children's Hospital Zurich

Exclusion Criteria:

* n.a.

Primary outcomes:
measure: Sucess rate
timeFrame: during study period, approx 15min
measure: Performance time
timeFrame: during study period, max 240 sec
Secondary outcomes:
measure: Secondary injuries
timeFrame: during study period, approx 15min
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Childrens Hospital, Department of Anaesthesia and Children's Research Centre
Study officials:
References:
Clinical trial NCT02413190: Bone Health in Facioscapulohumeral Muscular Dystrophy
Official title: Bone Health in Facioscapulohumeral Muscular Dystrophy: A Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Facioscapulohumeral Muscular Dystrophy
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Sponsor class: OTHER
Collaborators: name: Concord Hospital
name: FSHD Global Research Foundation
First posted: 2015-04-09
Enrollment: 94
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The population consists of individuals with Facioscapulohumeral Muscular Dystrophy.

Brief summary: This is a cross-sectional single visit study to determine bone health in individuals with FSHD.

Detailed description: Bone health will be assessed using 1) a DEXA scan to measure bone mineral density and lean body mass, and 2) blood tests of biomarkers of bone resorption and formation. These procedures will be correlated to measures of muscle strength testing and timed function tests to determine fracture risk in FSHD individuals considering age, gender, muscle strength and FSHD allele size.

Eligibility criteria: Inclusion Criteria:

* Genetic diagnosis of FSHD including chromosome 4 deletion and haplotype
* Age \> 18 years
* Ability to provide written informed consent for participation in the study
* Ability to participate in the DEXA scan

Exclusion Criteria:

* Unwillingness or inability to comply with the requirements of this protocol (in the opinion of the PI) including, but not limited to, the presence of any condition (physical, mental or social) that precludes the participant from comfortably and safely obtaining a DEXA scan, phlebotomy, or neurological examination

Primary outcomes:
measure: Bone Mineral Density in FSHD
timeFrame: Single visit
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Kennedy Krieger Institute, Johns Hopkins School of Medicine
state: Maryland
city: Sydney
country: Australia
facility: Concord Hospital Neurology Department, Hospital Road, Concord NSW 2139
Study officials:
References:
Clinical trial NCT03324490: Thoracic Spinal Versus Epidural Anesthesia for Nephrectomy in Obstructive/Restrictive Lung Disease Patients
Official title: Comparative Study of Mid-thoracic Spinal Versus Epidural Anesthesia for Open Nephrectomy in Patients With Obstructive/Restrictive Lung Disease: A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nephrectomy
Lung Diseases
Anesthesia
Keywords: Mid-thoracic spinal anesthesia
Mid-thoracic epidural anesthesia
Nephrectomy
Lung disease
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2017-10-27
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Using computer \& sealed envelope randomization, patients are assigned to receive either thoracic spinal anesthesia \[TSA group: n=30\] or thoracic epidural anesthesia \[TEA group: n=30\].
Primary purpose: SUPPORTIVE_CARE

Brief summary: Patients with respiratory disease have an increased risk of developing complications perioperatively. The use of regional anesthesia decreases this risk with better postoperative outcome. The aim of this study is to compare the safety and efficacy of thoracic spinal versus thoracic epidural anesthesia for open nephrectomy in patients with obstructive/restrictive lung disease.


Eligibility criteria: Inclusion Criteria:

* ASA class II or III
* Mild to moderate obstructive or restrictive lung disease
* Open nephrectomy candidate patients

Exclusion Criteria:

* Any condition contra-indicating regional anesthesia
* Allergic to any of the drugs used during the procedure

Primary outcomes:
measure: Patient Satisfaction Score
timeFrame: 24 hours
Secondary outcomes:
measure: VAS
timeFrame: 12 hours
measure: Mean ABP
timeFrame: 12 hours
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasr Al-Ainy Hospital, Cairo University
Study officials:
affiliation: Kasr Al-Ainy Hospital, Cairo University
name: Nazmy E Seif, MD
role: STUDY_CHAIR
affiliation: Kasr Al-Ainy Hospital, Cairo University
name: Ahmed M El-Badawy, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05273190: Stimulation of the Larynx to Treat Unexplained Chronic Cough
Official title: Vibrotactile Stimulation of the Larynx to Treat Unexplained Chronic Cough
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cough
Keywords: Chronic cough
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2022-03-10
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 88
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Researchers will test the effect of non-invasive vibrotactile stimulation of the larynx on symptom severity of unexplained chronic cough.


Eligibility criteria: Inclusion Criteria:

* Adults aged 18-88
* \>8 weeks of cough
* Cough visual analogue scale (VAS): Rating of 30 or greater on a 0-100 cough severity scale
* Ability to provide informed consent and independently complete questionnaires
* Ability to read and speak English

Exclusion Criteria:

* Electronic implants (e.g., pacemaker)
* Currently doing speech therapy for cough
* Contraindications to safe or effective VTS device use
* No regular access to wifi internet Neuromuscular impairment that may affect cough/laryngeal sensation and/or function (e.g., multiple system atrophy, Parkinson, CVA, vocal fold paralysis or paresis)
* Untreated carotid disease
* BMI \> 40 (for transmission of VTS through soft tissue)
* Current or recent (quit \< 3 months ago) smoking
* Known currently infectious cause for cough (e.g., TB, pertussis, COVID)
* History of known or suspected aspiration pneumonia
* Diagnosis or clinical suspicion of chronic obstructive pulmonary disease (COPD)
* Diagnosis or clinical suspicion of interstitial lung disease (ILD)
* Unmanaged reflux
* Unmanaged allergies/postnasal drip

Primary outcomes:
measure: Assess usability of VTS device
timeFrame: 3-7 weeks
measure: Impact of VTS on cough symptoms
timeFrame: 3-7 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Stephanie Misono
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04871490: Improving Detection and Early Action for HPV-positive Oropharynx Cancer
Official title: Improving Detection and Early Action for HPV-positive Oropharynx Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HPV Positive Oropharyngeal Squamous Cell Carcinoma
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
First posted: 2021-05-04
Enrollment: 40
Sex: ALL
Minimum age (years): 35
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study aims to determine whether a blood test for HPV DNA can improve diagnosis of HPV-positive oropharynx cancer (HPV-OPC).

Detailed description: The diagnosis of HPV-OPC is often delayed. In this study, individuals with signs or symptoms potentially related to HPV-OPC, such as unexplained throat pain, tonsil or tongue base asymmetry, or a neck mass, will have their blood tested for circulating HPV DNA. A positive test may indicate that their symptoms are caused by HPV-OPC, and their treating physician will be encouraged to complete all the necessary testing to determine whether this is the case.

Eligibility criteria: Inclusion Criteria:

* Neck mass present for \>2 weeks with no signs/symptoms of infection
* Neck mass present for \>2 weeks with signs/symptoms of infection that did not resolve with antibiotic therapy
* Palatine or lingual tonsillar asymmetry on physical exam
* Palatine or lingual tonsillar asymmetry on imaging, including asymmetric FDG uptake in palatine or lingual tonsils on PET-CT scans
* Unexplained throat pain for \>2 weeks that did not resolve with antibiotic therapy

Exclusion Criteria:

* Known diagnosis of HPV-OPC

Primary outcomes:
measure: Prevalence of circulating HPV DNA
timeFrame: Test results are returned within 1 week.
Secondary outcomes:
measure: Predictive value of circulating HPV DNA
timeFrame: Long-term follow-up for up to 2 years
measure: HPV-OPC awareness
timeFrame: At the time of study enrollment
measure: Impact on clinical practice
timeFrame: Within 2-3 weeks of study enrollment
Other outcomes:
Locations:
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
Study officials:
References:
Clinical trial NCT05360290: CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial
Official title: The Value of Circulating Tumor Cells in Patients With Breast Cancer Who Completed Surgery After Neoadjuvant Treatment: a Multicenter, Prospective Clinical Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Breast Cancer
Circulating Tumor Cell
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2022-05-04
Enrollment: 484
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients who completed surgery after neoadjuvant treatment.


Eligibility criteria: Inclusion Criteria:

* Female, aged ≥18 and ≤70 years;
* Histologically confirmed invasive breast cancer (cT2-4N0-2M0 or cT1N1-3M0 before neoadjuvant treatment);
* Completed neoadjuvant treamtment and surgery (within 4 years after surgery);
* Administered neoadjuvant chemotherapy (regardless of chemotherapy regimen);
* ECOG 0-1

Exclusion Criteria:

* Metastatic disease (Stage IV);
* Female patients who are pregnancy or lactation;
* Uncontrollable puncture site infection or systemic infection;

Primary outcomes:
measure: invasive disease-free survival (iDFS)
timeFrame: From surgery until time of event up to 3 years
Secondary outcomes:
measure: pathological complete response (pCR)
timeFrame: at surgery
measure: overall Survival (OS)
timeFrame: From surgery until time of event up to 3 years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Renji Hospital, School of Medicine, Shanghai Jiao Tong University
state: Shanghai
Study officials:
References: